Cardium Therapeutics Inc Share Price Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 45.93M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 93.51M | Net Debt 2020 | 874K 72.94M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Lois Chandler
COO | Chief Operating Officer | - | 01/10/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22/20/22 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |